Second-line erlotinib for non-small-cell lung cancer.
Medical Oncology Unit, Ospedale Vito Fazzi, Lecce, Italy.The Lancet Oncology (Impact Factor: 25.12). 04/2012; 13(4):e141-2; author reply e142. DOI: 10.1016/S1470-2045(12)70113-4
- Journal of Clinical Oncology 12/2012; · 17.88 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.